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Abstract
Vaccination with Plasmodium falciparum MSP142/complete Freund’s adjuvant (FA) followed by MSP142/incomplete FA is the
only known regimen that protects Aotus nancymaae monkeys against infection by erythrocytic stage malaria parasites. The
role of adjuvant is not defined; however complete FA cannot be used in humans. In rodent models, immunity is strain-
specific. We vaccinated Aotus monkeys with the FVO or 3D7 alleles of MSP142 expressed in Escherichia coli or with the FVO
allele expressed in baculovirus (bv) combined with complete and incomplete FA, Montanide ISA-720 (ISA-720) or AS02A.
Challenge with FVO strain P. falciparum showed that suppression of cumulative day 11 parasitemia was strain-specific and
could be induced by E. coli expressed MSP142 in combination with FA or ISA-720 but not with AS02A. The coli42-FVO
antigen induced a stronger protective effect than the bv42-FVO antigen, and FA induced a stronger protective effect than
ISA-720. ELISA antibody (Ab) responses at day of challenge (DOC) were strain-specific and correlated inversely with c-day 11
parasitemia (r=20.843). ELISA Ab levels at DOC meeting a titer of at least 115,000 ELISA Ab units identified the vaccinees
not requiring treatment (noTx) with a true positive rate of 83.3% and false positive rate of 14.3 %. Correlation between
functional growth inhibitory Ab levels (GIA) and cumulative day 11 parasitemia was weaker (r=20.511), and was not as
predictive for a response of noTx. The lowest false positive rate for GIA was 30% when requiring a true positive rate of
83.3%. These inhibition results along with those showing that antigen/FA combinations induced a stronger protective
immunity than antigen/ISA-720 or antigen/AS02 combinations are consistent with protection as ascribed to MSP1-specific
cytophilic antibodies. Development of an effective MSP142 vaccine against erythrocytic stage P. falciparum infection will
depend not only on antigen quality, but also upon the selection of an optimal adjuvant component.
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Introduction
Plasmodium falciparum is the leading cause of malaria morbidity
and mortality. Each year more than 300 million cases of clinical
malaria are reported, with deaths occurring primarily in children
[1]. Because development of immunity to malaria is due, at least
in part, to antibody (Ab) against erythrocytic stage parasites [2],
a malaria vaccine should include components that induce such
Ab. The major merozoite surface protein-1, MSP1, is a leading
erythrocytic stage vaccine candidate [3], and is one of the most
extensively studied of the malaria parasite antigens. It is secreted
as a 195-kDa precursor that is membrane anchored via
glycosylphosphatidylinositol [4] and is processed by proteases
producing fragments of 83, 28–30, 38–45 and 42 kDa [5–7].
During merozoite invasion, the 42 kDa fragment (MSP142)i s
further processed to produce a 33-kDa fragment (MSP133), and a
19 kDa C-terminal fragment (MSP119); the latter remains
attached to the surface of the merozoite during invasion [8,9].
MSP119 is comprised of two tandem epidermal growth factor-
like (EGF) domains [8] each containing three disulfide bridges
[10], which force the assembly of several well-defined discontin-
uous epitopes [11–13]. Despite all that is known of MSP1
structure, little is known of its biological function, although there is
evidence that MSP1 binds to erythrocytes and may have a role in
erythrocyte invasion [14–16].
Evidence supporting the use of MSP142 or its MSP119 portion
as a malaria vaccine is extensive. MSP119-specific monoclonal Abs
inhibit P. falciparum growth in vitro [17] and passively protect mice
against infection with P. yoelii, [18,19]. Immunization of Aotus
monkeys with native P. falciparum MSP1, [20], baculovirus-
expressed recombinant MSP142 [21,22], E. coli expressed
PLoS ONE | www.plosone.org 1 July 2008 | Volume 3 | Issue 7 | e2830MSP142 [23,24] or Saccharomyces cerevisiae recombinant MSP119
[25], protect against homologous challenge. E. coli-expressed P.
yoelii MSP119 protects against a homologous challenge in rodent
models [19,26]. Anti-sera raised against recombinant MSP142
inhibit P. falciparum growth in vitro [27–30], or inhibit secondary
processing of MSP142 [31]. MSP119-specific antibodies from
immune residents of malaria endemic areas also appear to play a
predominant role in merozoite invasion inhibition [32]. Recently,
however, the value of these in vitro assays has come into question
because cytophilic MSP1-specific Ab appear to be more important
for controlling infection than previously thought [33,34].
In this current work we expand on previous work [24] to show
the protective effect of vaccinating Aotus monkeys with three
different recombinant p42 fragments of MSP1 varied according to
both antigen (Ag) and adjuvant. Animals given 3D7 strain
MSP142, which is heterologous to the FVO challenge strain were
not protected by vaccination, and animals given homologous
strain FVO MSP142 in combination with complete and incom-
plete Freund’s adjuvant (FA) had greater chance of being
protected than those given homologous Ag in combination with
Montanide ISA-720. Animals given homologous Ag in combina-
tion with AS02A were not protected by vaccination. Protection
correlated with ELISA-specific Ab measured with recombinant
MSP142 and its fragments, and correlated with growth inhibitory
responses when measured against FVO but not the 3D7 strain of
P. falciparum. In two separate experiments, animals given vaccine in
combination with Montanide ISA-720 showed a significant
capacity for inducing protection against infection, with most
animals remaining untreated or treated for anemia. Our results
may relate, in part, to these adjuvants’ respective capacities for
guiding the development of TH1 based immunity, and indicate
that an effective malaria vaccine based on MSP142 will depend not
only on Ag quality but also adjuvant selection.
Results
Vaccination and Challenge
Aotus monkeys were immunized with various Ag/adjuvant
combinations and challenged intravenously with 1610
4 FVO
strain P. falciparum (Table 1, 2 and 3).
Affect of Vaccination on Treatment Outcome.
Inspection of the results in Table 1, 2 and 3 shows that the
different vaccination regimens induced responses having different
effects on the possible treatment outcomes, which are defined as
noTx (no treatment owing to self cure), TxA, (treatment for
anemia), or TxP (treatment for uncontrolled parasitemia). This
observation was supported by Fisher’s exact test (p=0.00046).
Table 1. Trial Design and Results for Adjuvant CFA/FA
Regimen Ag Monkey Day 11 Tx Status GIA ELISA Ab Units
ELISA Ab Titer (E.coli
expressed)
3D7 GIA FVO GIA
bv42
(FVO)
bv42
(3D7) EGF1 EGF2 p19 p42
1 Pvs25 2865 39,461 TxP 6.7% 218.0% 5.35610
1 9.30610
1 n/d n/d n/d n/d
2869 125,361 TxP 13.1% * 7.40610
1 7.90610
1 n/d n/d n/d n/d
2891 23,521 TxP 11.2% 25.9% 3.95610
1 4.80610
1 n/d n/d n/d n/d
2909 99,231 TxP 3.1% 9.8% 3.48610
1 1.60610
1 n/d n/d n/d n/d
2916 18,761 TxP 16.5% 11.8% 1.04610
2 1.12610
2 n/d n/d n/d n/d
2 coli42 (3D7) 2882 159,381 TxP 22.4% 22.7% 1.74610
4 2.21610
4 5.52610
4 3.50610
3 2.75610
5 3.54610
5
2886 11,431 TxP 4.1% 0.1% 5.10610
4 6.42610
4 3.09610
5 3.01610
4 1.17610
6 1.53610
6
2887 1,111 TxA 20.3% 21.7% 3.66610
4 4.07610
4 2.22610
5 2.42610
4 6.05610
5 6.95610
5
2908 43,501 TxP 27.6% 18.5% 5.86610
4 9.72610
4 6.16610
5 6.24610
4 1.32610
6 2.11610
6
2941 11,401 TxP 33.9% 48.1% 2.94610
4 5.80610
4 3.92610
5 2.19610
4 1.26610
6 1.22610
6
2948 701 TxP 3.6% 217.1% 2.12610
4 3.19610
4 1.68610
5 6.99610
3 3.53610
5 5.46610
5
3 coli42 (FVO) 2863 612 TxA 22.4% 45.6% 2.06610
5 1.18610
5 7.83610
5 6.32610
4 1.02610
6 4.36610
6
2899 13 noTx 51.4% 47.3% 3.77610
5 3.09610
5 1.32610
6 2.95610
5 1.55610
6 8.34610
6
2900 31 TxA 40.4% 34.2% 2.84610
5 2.79610
5 1.42610
6 6.96610
4 1.31610
6 5.37610
6
2905 25 noTx 21.9% 15.8% 1.15610
5 1.19610
5 1.12610
6 7.54610
4 1.44610
6 4.06610
6
2929 34 noTx 63.7% 64.4% 2.68610
5 2.15610
5 1.23610
6 5.41610
4 1.18610
6 5.20610
6
2931 13 noTx 27.5% 50.0% 2.38610
5 1.85610
5 1.28610
6 1.43610
5 1.47610
6 5.98610
6
7 bv42 (FVO) 2872 160 TxA 12.0% 27.9% 7.66610
4 6.50610
4 1.94610
5 2.03610
4 3.81610
5 1.53610
6
2875 790 TxA 4.7% 24.4% 8.08610
4 5.71610
4 2.51610
5 8.96610
3 3.22610
5 1.44610
6
2930 1,690 TxP 19.5% 48.3% 1.19610
5 1.04610
5 6.94610
5 5.81610
3 6.98610
5 2.62610
6
2939 141 noTx 19.3% 28.3% 1.20610
5 9.71610
4 4.40610
5 1.12610
4 6.88610
5 2.77610
6
2949 5,920 TxP 9.3% 50.5% 9.18610
4 6.83610
4 2.44610
5 1.22610
4 4.37610
5 2.31610
6
Aotus monkeys vaccinated with Ag in combination with FA. Groups of six animals were vaccinated. Day 11 is c-day 11 parasitemia. Tx is treatment outcome: noTx,n o
treatment required; TxA treatment for anemia; TxP, treatment for uncontrolled parasitemia. GIA is in vitro growth/invasion inhibition against FVO or 3D7 strain P.
falciparum. ELISA Ab units were determined with 3D7 or FVO strain MSP142 expressed in baculovirus. ELISA Ab titers were determined with 3D7 or FVO strain MSP142,
p19, EGF1 or EGF2 expressed in E. coli, and assays were run only using Ag homologous to the vaccine strain. Some results from regimens 1, 3 and 7 were reported
previously [24]. n/d is not done.
*, no sample available.
doi:10.1371/journal.pone.0002830.t001
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FA), regimen 7 (bv42-FVO/FA), and regimen 8 (coli42-FVO/
ISA-720), induced any noTx responses. All three of these
‘‘protective’’ vaccines were comprised of Ag that is homologous
to the challenge strain. Of these three regimens, only one had a
matching regimen that matched on everything except for antigen
strain (vaccine regimen 3, coli42-FVO, is matched with vaccine
regimen 2, coli42-3D7). A Wilcoxon-Mann Whitney (WMW) test
Table 2. Trial Design and Results for Adjuvant AS02A.
Regimen Ag Monkey Day 11 Tx Status GIA ELISA Ab Units ELISA Ab Titer (E.coli expressed)
3D7 GIA FVO GIA bv42 (FVO) bv42 (3D7) EGF1 EGF2 p19 p42
4 Nothing 1784 368,931 TxP 22.5% 12.1% 3.48610
1 2.30610
1 n/d n/d n/d n/d
1787 78,521 TxP 38.8% 13.4% 3.48610
1 2.00610
1 n/d n/d n/d n/d
2801 228,722 TxP 210.7% 23.4% 3.48610
1 1.40610
1 n/d n/d n/d n/d
2808 307,351 TxP 21.3% * 3.48610
1 1.60610
1 n/d n/d n/d n/d
2885 314,931 TxP 8.6% * 3.48610
1 9.00E+00 n/d n/d n/d n/d
2904 72,021 TxP 8.9% 16.2% 3.48610
1 8.00E+00 n/d n/d n/d n/d
5 coli42 (3D7) 2789 86,581 TxP 11.9% 29.9% 1.28610
4 1.17610
4 4.79610
4 2.78610
2 1.07610
5 1.02610
5
2807 119,531 TxP 9.0% 230.9% 1.12610
4 1.32610
4 3.09610
4 2.93610
2 1.08610
5 1.06610
5
2890 143,611 TxP 16.1% 19.5% 1.11610
3 2.12610
3 6.29610
3 5.00610
1 1.25610
4 1.45610
4
2902 70,491 TxP 13.5% 15.2% 7.94610
3 1.41610
4 2.83610
4 3.58610
2 1.02610
5 1.16610
5
2921 26,771 TxP 39.6% 3.0% 4.04610
4 4.99610
4 2.46610
5 1.13610
3 4.81610
5 4.85610
5
2943 12,731 TxP 2.0% 210.8% 4.27610
3 6.70610
3 2.72610
4 5.00610
1 4.57610
4 4.93610
4
6 coli42 (FVO) 2884 141,451 TxP 210.4% 233.1% 5.29610
3 4.40610
3 2.89610
4 6.79610
2 4.59610
4 8.61610
4
2901 10,351 TxP 12.9% 9.9% 4.67610
3 5.87610
3 2.81610
4 1.11610
3 4.59610
4 5.45610
4
2903 24,541 TxP * * 4.43610
3 5.76610
3 4.13610
4 2.95610
2 5.51610
4 1.12610
5
2914 128,271 TxP 36.2% 52.9% 6.95610
3 8.17610
3 6.07610
4 2.09610
2 9.24610
4 1.16610
5
2926 111,721 TxP 26.6% 5.5% 6.70610
3 8.24610
3 6.06610
4 2.54610
2 1.08610
5 1.67610
5
Aotus monkeys vaccinated antigens in combination with AS02A. Groups of six animals were vaccinated. Day 11 is c-day 11 parasitemia. Tx is treatment outcome: noTx,
no treatment required; TxA treatment for anemia; TxP, treatment for uncontrolled parasitemia. GIA is in vitro growth/invasion inhibition against FVO or 3D7 strain P.
falciparum. ELISA Ab units were determined with 3D7 or FVO strain MSP142 expressed in baculovirus. ELISA Ab titers were determined with 3D7 or FVO strain MSP142,
p19, EGF1 or EGF2 expressed in E. coli, and assays were run only using Ag homologous to the vaccine strain.
n/d is not done.
*, no sample available.
doi:10.1371/journal.pone.0002830.t002
Table 3. Trial Design and Results for Adjuvant Montanide ISA-720
Regimen Ag Monkey Day 11
Tx
Status GIA ELISA Ab Units ELISA Ab Titer (E.coli expressed)
3D7 GIA FVO GIA bv42 (FVO) bv42 (3D7) EGF1 EGF2 p19 p42
8 coli42
(FVO)
1786 18,720 noTx 15.2% 35.9% 5.34610
4 4.39610
4 2.06610
5 2.43610
4 4.42610
5 1.06610
6
2806 67,830 TxA 213.1% 6.8% 3.64610
4 3.39610
4 1.98610
5 5.34610
3 3.74610
5 1.09610
6
2876 600 TxP 26.5% 9.9% 1.94610
4 1.73610
4 4.96610
4 6.09610
3 1.22610
5 3.01610
5
2911 7,300 TxP 43.5% 7.9% 7.67610
3 9.29610
3 3.76610
4 2.27610
3 5.75610
4 1.84610
5
2940 10,190 TxP 3.4% 41.2% 2.83610
4 2.55610
4 2.45610
5 1.97610
4 4.68610
5 7.28610
5
9 bv42
(FVO)
1788 10,040 TxA 0.5% 3.1% 6.34610
4 4.91610
4 4.51610
5 5.59610
3 3.81610
5 2.20610
6
2792 118,810 TxP 41.1% 233.6% 7.34610
3 6.69610
3 4.28610
4 2.45610
2 3.97610
4 1.24610
5
2867 41,020 TxP 28.5% 27.7% 1.31610
4 1.15610
4 4.93610
4 5.17610
2 4.62610
4 5.13610
5
2917 70,220 TxP 22.4% 16.8% 1.44610
4 1.74610
4 4.13610
4 5.00610
1 4.67610
4 2.70610
5
2920 121,370 TxP 38.3% 24.6% 2.59610
3 3.16610
3 1.34610
4 1.94610
2 1.15610
4 5.22610
4
2942 24,150 TxP 8.3% 3.6% 7.25610
3 8.18610
3 5.04610
4 7.86610
2 4.44610
4 1.24610
5
Aotus monkeys vaccinated with one of three MSP142 antigens in combination with ISA-720. Groups of six animals were vaccinated. Day 11 is c-day 11 parasitemia. Tx is
treatment outcome: noTx, no treatment required; TxA treatment for anemia; TxP, treatment for uncontrolled parasitemia. GIA is in vitro growth/invasion inhibition
against FVO or 3D7 strain P. falciparum. ELISA Ab units were determined with 3D7 or FVO strain MSP142 expressed in baculovirus. ELISA Ab titers were determined with
3D7 or FVO strain MSP142, p19, EGF1 or EGF2 expressed in E. coli, and assays were run only using Ag homologous to the vaccine strain.
doi:10.1371/journal.pone.0002830.t003
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antigen regimen (p=0.0065). This suggests that the protective
effect was strain-specific. Vaccines adjuvanted with AS02A did not
induce a protective effect.
Strain-specific MSP142-specific ELISA Ab Responses
Day of Challenge sera (DOC sera) were evaluated by ELISA
against the 3D7 and FVO alleles of MSP142 expressed in
baculovirus to determine if the strain specific protective affect of
vaccination was also apparent in the Ab responses. As shown in
Fig. 1A and B, there is a general tendency for the Ab response
against homologous Ag to exceed that measured against
heterologous Ag (p,0.0001 by Wilcoxon signed rank test),
especially for the samples containing higher Ab levels. These
results can also be observed in Table 4, which, through a series of
paired t-tests, also shows that the Ag/FA but not the Ag/AS02A or
Ag/ISA-720 combinations induced significant strain-specific Ab
responses.
Models Evaluating the Affect of Adjuvant and Antigen on
Response
We used a cumulative logit model to begin addressing the
observation, from Table 1 and 3, that antigen and adjuvant
affected treatment outcome. Because the study design was not
balanced with respect to antigens and adjuvants, and because
several vaccine regimens had all monkeys responding with the
worst response (TxP), many of the simple models listed in Table 5
would not converge if all the data were included. Thus, the models
were restricted to the twenty-two animals from vaccine regimens 3,
7, 8 and 9 (Table 1 and 3). These four vaccine regimens create a
balanced 2 by 2 design, comparing two levels of antigen (bv42-
FVO and coli42-FVO) with two levels of adjuvant (FA and ISA-
720). Responses from these animals were treated as ordinal, with
the best response being those that did not require treatment
(noTx), the next better response being those treated for anemia
(TxA), and the worst response being those treated for uncontrolled
parasitemia (TxP). Model 3 (Table 5) had the lowest Akaike’s
Information Criterion (AIC), and the model says that the odds of
making a response of noTx compared to either of TxA or TxP is
12.47 times greater for FA than for ISA-720 [95% confidence
interval (1.96, 115.2)], regardless of the antigen (p=0.0374). It
further says that the odds of making a response of noTx compared
to either of TxA or TxP is 6.71 times greater for coli42-FVO than
for bv42-FVO [95% confidence interval (1.11, 53.5)], regardless of
the adjuvant (p=0.00649). Thus adjuvant and Ag both contrib-
uted significantly to the induction of responses that effected
treatment outcome.
Next we used a general linear model (GLM) to determine if
antigen and adjuvant affected the log(c-day 11 parasitemia) among
the same animals (regimens 3, 7, 8, and 9) as used in the
cumulative logit model above. We tried the 5 models in Table 5
for this regression and also chose model 3 by AIC. The model
showed a strong effect for adjuvant (ISA-720 had on average
1.9540 times higher log10(c-day 11 parasitemia) responses than
FA, p,0.0001) and antigen (bv42-FVO had on average 1.3627
times higher log10(c-day 11 parasitemia) responses than coli42-
FVO, p=0.001). This model had a strong coefficient of
determination (R
2 (adjusted)=0.7904). The responses evaluated
with this model are shown graphically in (Fig. 2A). In Fig. 2B we
show the marginal means from the model, where for example, the
marginal mean for the bv42 antigen represents the modeled mean
for that antigen averaged over both adjuvants. This model agrees
qualitatively with the cumulative logit model, with both models
showing that the beneficial effect of FA over ISA-720 is about
twice as large as the beneficial effect of coli42-FVO over bv42-
FVO.
We then used the same GLM (Model 3) to examine the affect of
adjuvant and antigen on the induction of Ab responses that were
Figure 1. Individual value plots showing strain-specific Ab
responses by ELISA for vaccine recipients. Responses are grouped
by vaccine strain received and then by the Ag strain use for ELISA. Panel
A includes all 3D7 strain vaccine recipients in the trial. Panel B includes
all FVO strain vaccine recipients in the trial. Connect lines join each
individual animal’s ELISA Ab response measured with the FVO Ag to
that measured with the 3D7 Ag. Both Ag were expressed in baculovirus.
doi:10.1371/journal.pone.0002830.g001
Table 4. Group Wise Comparisons of Adjuvant Effect on
Induction of Strain-specific Ab Responses
Adjuvant Ag Ag-specific ELISA Ab Units
1
FVO (mean) 3D7 (mean) paired t-test p
FA coli42(3D7) 33,688 52,343 0.033
coli42(FVO) 248,067 203,983 0.029
bv42(FVO) 97,520 78,200 0.001
AS02A coli42(3D7) 12,944 16,299 0.085
coli42(FVO) 5,608 6,485 0.121
ISA-720 coli42(FVO) 29,026 25,963 0.162
bv42(FVO) 18,008 15,990 0.462
1ELISA Ab units were determined with 3D7 and FVO strain MSP142 expressed in
baculovirus.
doi:10.1371/journal.pone.0002830.t004
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well as those that were reactive in ELISA with various
constructions of MSP142 and its fragments. Growth inhibitory
Ab responses did not require transformation for this analysis
(Fig. 3A), while all of the ELISA Ab responses were transformed to
the square root (Fig. 4A). In all cases variance testing could not
rule out the assumptions that grouped responses were normally
distributed and had the same variances.
When %Inhibition against FVO strain P. falciparum was the
response term, the model showed a strong effect for adjuvant (FA
had on average 2.9037 times higher %Inhibition responses than
ISA-720, p,0.003) but affect of antigen was not significant
(p=0.185). This model had a weak coefficient of determination
(R
2 (adjusted)=0.3819). The responses evaluated with this model
are shown graphically in (Fig. 3A), with estimated marginal means
shown in Fig. 3B. When %Inhibition against 3D7 strain P.
falciparum was the response term, neither adjuvant nor antigen had
a significant affect on the model (Fig. 3B).
Evaluation of the baculovirus-expressed FVO-ELISA Ab Units
response in the GLM (Model 3) showed that both adjuvant and
antigen had significant main effects on the model. FA had on average
2.8818 times higher FVO strain ELISA Ab responses than ISA-720
(p,0.001)and coli42-FVOhad on average1.6920 timeshigher FVO
strain ELISA Ab responses than bv42-FVO, (p,0.001). The model
had a strong coefficient of determination, (R
2 (adjusted)=0.9306).
The responses evaluated with this model are shown graphically in
Fig. 4A (leftside);estimated marginal meansare shown in Fig.4B (left
side). The same pattern of results and significances were obtained
when this GLM was tested with 3D7 ELISA Ab responses,
R
2=0.771, Figs 4A and 4B (right side). For both models the affect
of adjuvant was about 2 times greater than the affect of antigen.
Correlations between c-day 11 parasitemia and serologic
responses
Pearson’s tests on responses from the twenty-seven monkeys
vaccinated with any FVO Ag in combination with any adjuvant
(vaccine regimens 3, 6, 7, 8, 9 in Table 1 and 3) showed significant
correlations between log(c-day 11 parasitemia) and the %
Inhibition response against FVO strain but not 3D7 P. falciparum
(Fig. 5A, r=20.511, p=0.008 and Fig. 5B, r=20.327, p=0.103,
respectively). These tests also showed significant inverse correla-
tions between c-day 11 parasitemia and ELISA Ab responses
measured with both baculovirus expressed FVO strain and 3D7
strain MSP142 (Fig. 5C, r=20.843, p,0.001 and Fig. 5D,
r=20.861, p,.001, respectively)
We further investigated the possibility that each of the 4 pre-
challenge covariates of Fig. 5 could be used for predicting an
outcome of self-cure (noTx required) by evaluating Receiver
Operation Characteristic (ROC) graphs (not shown). This
grouping of animals contained six true positive results (self cure)
and twenty-one true negative results (TxA or TxP). In Table 6, we
show threshold values that give the smallest false positive rates
given a true positive rate of 83.3% or greater. Neither GIA assay
had good predictive value for predicting the outcome of noTx
required because the false positive rate for the 3D7 assay and the
FVO assay were 40% and 30%, respectively, when their threshold
%Inhibition responses (15.4% and 28.3%, respectively) were set to
detect 83.3% of true positives. The 3D7 and FVO MSP142 ELISA
assays were both predictive for the outcome of noTx, with both
detecting a false positive rate of 14.3% when their threshold
responses (97,100 ELISA units and 115,400 ELISA units,
respectively) were set to detect 83.3% of true positives.
MSP142 fragment-specific Ab Responses
In an attempt to improve the sensitivity and specificity of ELISA
for detecting animals that would not require treatment we
evaluated the ELISA Ab responses to E. coli expressed MSP142
from the FVO strain of P. falciparum and its three fragments,
MSP119 (P19), EGF1, and EGF2. For the twenty-seven animals in
vaccine regimens 3, 6, 7, 8 and 9, all of the ELISAs detected
responses showed significant inverse correlations with c-day 11
Table 5. Cumulative Logit Models used to Evaluate the
Relationship between Treatment Outcome and Adjuvant and
Antigen
Model 0 No effect of antigen and no effect of adjuvant
Model 1 Main effect from antigen but no effect from adjuvant
Model 2 No effect from antigen but main effect from adjuvant
Model 3: Main Effects from both
Model 4: Main effects plus an interaction term
doi:10.1371/journal.pone.0002830.t005
Figure 2. C-day 11 parasitemias for regimens 3, 7, 8, and 9
grouped by adjuvant and antigen. Open circles, individual
responses; filled circles, means; bar is the 95% confidence interval for
the mean. Panel A compares grouped log(c-day 11 parasitemia) levels.
Panel B shows the estimated marginal means from the GLM used to
analyze the responses.
doi:10.1371/journal.pone.0002830.g002
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for response levels giving a true positive rate of 83.3% or greater
are shown in Table 7. Although all of the ELISA assays were
predictive for the outcome of noTx, the assays based on measuring
Ab to either EGF2 and MSP142 were best. Both assays detected a
false positive rate of 9.5% when their threshold ELISA Ab
response levels (2.4610
4 and 2.7610
6, respectively) were set to
detect 83.3% of true positives. Because of the small sample sizes,
however, further work is needed to differentiate between the
abilities of the different ELISA assays to predict outcome.
Protection Induced by coli42-FVO/ISA-720
We were most interested in determining if the protective effect
induced by the coli42-FVO/ISA-720 regimen (Table 3) was
significant because of the possibility that this combination would be
acceptable for human use (Fig. 6, Trial 1). WMW tests showed that c-
day 11 parasitemia levels were significantly lower among animals
receiving coli42-FVO/ISA-720 (median 1.0610
4 parasites/ml) than
among AS02A controls (median 2.7610
5 parasites/ml, p=0.004).
A second trial (Fig. 6, Trial 2) was designed to confirm our
observation of the protective effect of coli42-FVO/ISA-720 by
including a proper ISA-720 control and by using more animals
(N=8). In the first trial in the coli42-FVO/ISA-720 group, one
of five animals did not require treatment, one was treated for
anemia, and three were treated for uncontrolled parasitemia
(Table 3). In the second trial two of seven animals did not
require treatment, three were treated for anemia, and two were
treated for uncontrolled parasitemia. The eighth animal, which
appeared to be controlling its infection, died prematurely during
handling (data not shown). WMW tests showed that c-day 11
parasitemia levels were significantly lower among animals
receiving coli42-FVO/ISA-720 (median 1.6610
4 parasites/ml)
than among animals receiving ISA-720 adjuvant alone (median
2.5610
5 parasites/ml, p=0.0054). No differences in parasitemia
were observed between the control groups (p=1.0000) or the
vaccine groups (p=0.9417) of the two trials. These results
confirm that coli42-FVO/ISA-720 induces some protective
immunity in Aotus monkeys.
Figure 3. Growth/invasion inhibition for regimens 3, 7, 8, and 9 grouped by adjuvant and antigen. Open circles, individual responses;
filled circles, means; bar is the 95% confidence interval for the mean. Panel A compares grouped %Inhibition levels. Panel B shows the estimated
marginal means from the GLM used to analyze the responses.
doi:10.1371/journal.pone.0002830.g003
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Our primary objectives for this study were to determine if
vaccination with E. coli expressed MSP142-FVO or 23D7 or
baculovirus expressed MSP142-FVO in combination with FA, or
the human use adjuvants AS02A or ISA-720 induced a protective
immune response against FVO strain P. falciparum challenge.
Secondly we sought to identify Ab dependent correlates of
protection.
The overarching results of the trial were that the protective
effects of vaccination are strain-specific and depended on the
combination of adjuvant and Ag used for vaccination. Both FVO
strain antigens used in this study protected against FVO challenge
but 3D7 strain antigen did not, and the antigens also induced
antibodies having a significant strain-specific component as
measured by ELISA. One of the protective combinations was
coli42-FVO/ISA-720, which is compatible with human use.
Although observed previously in rodent models of malaria [35–
37], this is the first time that a P. falciparum challenge model has
shown that a P. falciparum erythrocytic stage vaccine can induce a
significant protective effect when combined with an adjuvant
considered suitable for human use.
Statistical models evaluating the requirement to treat (cumula-
tive logit model) or the suppression of c-day 11 parasitemia (GLM)
showed that both adjuvant (FA superior to ISA-720) and antigen
(coli42-FVO superior to bv42-FVO) affected the induction of
protective effects against erythrocytic stage FVO strain P.
falciparum. The GLM for ELISA Ab response (capture antigens
expressed in baculovirus) showed that for both homologous and
heterologous MSP142 Ag, the level of Ab induction was both
adjuvant and Ag dependant. ROC calculations prepared with
results from vaccine recipients given any FVO strain MSP142 Ag/
Adjuvant combination showed that p42-specific and EGF2-
specific ELISA Ab levels (capture antigens expressed in E. coli)
had the best predictive value for identifying animals with an
outcome of noTx, with both detecting a false positive rate of 9%
when their threshold responses (ELISA Ab titer=2.7610
6 and
2.4610
3, respectively) were set to detect 83.3% of true positives.
The small improvement obtained by using the MSP142 Ag
Figure 4. ELISA Ab responses for regimens 3, 7, 8, and 9
grouped by adjuvant and antigen. Capture Ags were expressed in
baculovirus. Open circles, individual responses; filled circles, means; bar
is the 95% confidence interval for the mean. Panel A compares grouped
ELISA Ab unit levels. Panel B shows the estimated marginal means from
the GLM used to analyze the responses.
doi:10.1371/journal.pone.0002830.g004
Figure 5. Correlation between log(c-day 11 parasitemia) and serologic response in animals vaccinated with FVO strain Ag. Animals
were vaccinated with either E. coli or baculovirus expressed MSP142 in combination with FA, ISA-720 or AS02A. Growth/Invasion inhibition is against
FVO (Panel A) or 3D7 (Panel B) strain targets. ELISA was performed with recombinant FVO (Panel C) or 3D7 (Panel D) strain MSP142 expressed in
baculovirus. Correlations were determined with Pearson’s test after testing data distributions for normality.
doi:10.1371/journal.pone.0002830.g005
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in baculovirus may be due to either chance or to simple protein
glycosylation by baculovirus. Study design did not allow us to
formally examine the contributions of AS02A adjuvant or coli42-
3D7 Ag to the induction of protective responses; however,
inspection of the results in Tables 1 and 2 indicates that neither
of these factors participated in this process.
In apposition to the argument that immunity was strain specific,
is that protection depends only on immunogenicity. ANOVA (data
not shown) indicates that, when tested by ELISA with all
permutations of capture Ag strain, the immunogenicity of
coli42-3D7/FA was significantly lower than that of coli42-FVO/
FA, but the immunogenicities of the protective coli42-FVO/ISA-
720 combination and the non-protective coli42-3D7/FA combi-
nation were not different. This suggests that coli42-3D7/FA
should have been able to induce a measurable protective effect if
immunogenicity is the controlling factor rather than the induction
of strain dependent immunity.
We used a GLM to show that the induction of growth inhibitory
Ab was adjuvant dependant (FA superior to ISA-720) but not
antigen dependent. Similarly to what has been observed
previously, c-day 11 parasitemia correlated inversely with growth
inhibition against FVO strain P. falciparum [28]. Similar but less
extreme and non-significant inverse correlations were seen for 3D7
strain P. falciparum. The difference in these correlations might be
attributable to MSP142 related strain-dependant differences in the
mechanisms of invasion/growth inhibition [30]. ROC graphs
showed that GIA assays were not as useful for predicting an
outcome of noTx as ELISA assays.
The affect of adjuvant on the induction of protection is complex
and requires further study. ELISA reactive Ab correlated well with
the induction of protective immunity as shown previously [28].
However it was the Ag/FA combinations that had the greatest
affect on the induction of these responses. Five of the six animals
that self cured their infections received FA as the adjuvant, and
these five animals all had Ab levels exceeding the threshold values
for predicting noTx from the ROC graphs. Furthermore, Ag/FA
combinations induced more Ab reactive with homologous Ag than
heterologous Ag, but Ag/AS02A or Ag/ISA-720 combinations did
not show this affect.
FA may have supported the induction of a strong TH1 based
immune response and appears to have a higher capacity for
inducing such responses than Montanide ISA-720 which in turn
seems to be more potent in this regard than AS02A [38]. This
property of FA further supports the importance of the Fc region in
Ab-mediated immunity against erythrocytic stage malaria infec-
tion [34]. Inflammatory responses induce by FA, such as induction
of IFN-gamma and TGF-beta, play a critical role in Ig class
switching and thus in the promotion of cytophilic Ab responses
[39]. Recently, a chimeric mouse model for human immunity
against P. falciparum was used to show that the Ab Fc region plays
an important role in Ab mediated protection against erythrocytic
stage malaria parasite infection [34]. Furthermore, this protection
was unrelated to the induction of invasion inhibitory Ab; Fc
fragment mediated processes are not measured in most GIAs [34].
Adjuvant selection will be a critical component of MSP142
based vaccine development for humans. There is a proposal that
IFA be used for vaccinating residents of malaria endemic areas
against P. falciparum [40]. However, if the induction of TH1 based
immunity is, indeed, an important component of the induction of
protective immunity, it does not appear that IFA offers an effective
strategy [41,42] unless it is supplemented with stimulants such as
CpG [42]. Other, perhaps more suitable, adjuvant possibilities
include Montanide ISA-720 supplemented with CpG [43] or
AS01B [44].
Materials and Methods
Recombinant Expression Plasmids
Plasmids for expression of GST/EGF-like domain 1 and GST/
EGF-like domain 2 from the 3D7 and FVO strains of P. falciparum
MSP1 and p19 from the FVO strain were constructed previously
Table 6. Results from ROC graphs for Predicting noTx by Using GIA or ELISA with Ag Expressed in Baculovirus
Response False Positive Rate True Positive Rate Threshold
% Inhibition 23D7 Targets 40% 83.3% 15.2% Inhibition
% Inhibition – FVO Targets 30% 83.3% 28.3% Inhibition
ELISA Ab Units 23D7 Strain 14.3% 83.3% 97,100 ELISA Units
ELISA Ab Units – FVO Strain 14.3% 83.3% 115,400 ELISA Units
Responses evaluated were from the twenty-seven animals in vaccine regimens 3, 6, 7, 8 and 9, vaccinated with any FVO Ag in combination with any adjuvant (Table 1, 2
and 3). Responses larger than the threshold value predict noTx outcome. %Inhibition is in vitro growth/invasion inhibition against FVO or 3D7 strain P. falciparum. ELISA
Ab units were determined with 3D7 or FVO strain MSP142 expressed in baculovirus.
doi:10.1371/journal.pone.0002830.t006
Table 7. Results from ROC graphs for Predicting Self-Cure by Using ELISA with FVO strain Ag expressed in E. coli
Response False Positive Rate True Positive Rate Threshold for ELISA Ab Titer
ELISA Ab Titer – EGF1 19% 83.3% 4.0610
5
ELISA Ab Titer – EGF2 9.5% 83.3% 2.4610
3
ELISA Ab Titer – p19 14.3% 83.3% 6.5610
5
ELISA Ab Titer – p42 9.5% 83.3% 2.7610
6
Responses evaluated were from the twenty-seven animals in vaccine regimens 3, 6, 7, 8 and 9, vaccinated with any FVO Ag in combination with any adjuvant (Table 1, 2
and 3). ELISA Ab titers were determined with FVO strain MSP142, p19, EGF1 or EGF2 expressed in E. coli, which are homologous to the vaccine strain.
doi:10.1371/journal.pone.0002830.t007
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prepared by cloning the appropriate PCR-synthesized fragment
into the BamHI (5’) and NotI (3’) sites of pGEX-6p. The insert was
sequenced to verify reading frame and primary structure.
Recombinant protein expression and purification
MSP142-FVO and -3D7 were expressed in baculovirus (bv) or E.
coli (coli) and purified as described previously [22,24,31,46]. GST
fusion proteins corresponding to the p19, EGF1, and EGF2
fragments of MSP142 were expressed in E. coli and purified as
described previously [24].
Vaccination and Challenge of Aotus Monkeys
Groups of six animals were immunized with coli42-FVO,
coli42-3D7, bv42-FVO, or the P. vivax sexual stage protein Pvs25
given with Freund’s Complete and Incomplete adjuvant (FA),
Montanide ISA-720 (Seppic, ISA-720), or AS02A (GSK) (Table 1,
2 and 3). Pre-immune sera were collected 2 weeks (Time -2) prior
to the first immunization. Animals given Ag/AS02A or Ag/ISA-
720 combinations were vaccinated at weeks 0, 4, 12, and 24.
Those given Ag/FA combinations were vaccinated at week 12
with Ag/complete FA and at week 19 with Ag/incomplete FA.
Vaccinations were with 50 mg of Ag. All animals were challenged
intravenously at week 26 with 1610
4 FVO strain P. falciparum
taken from a donor monkey. Generally, the severity of the
response induced by Freund’s adjuvants in Aotus monkeys limits
the number of immunizations to no more than three. It was our
intention to vaccinate the monkeys given Ag/FA combinations
three times at four week intervals beginning at week twelve of the
study, and then challenge two weeks after the last immunization.
However, unexpectedly severe responses after priming forced us to
delay the second immunization by three weeks and ultimately to
eliminate the third immunization. Nevertheless, these animals
were challenged at the same time as the one given Ag mixed with
the other adjuvants.
Beginning 3 days after the challenge, parasite density was
quantified from Giemsa-stained thick blood films; when parasite
counts exceeded 80,000/mL of blood, parasite densities were
quantified from thin blood smears. Blood smears were prepared
daily and evaluated for 56 days after the challenge. Monkeys that
developed high-density parasitemia (TxP, 200,000 parasites/mLo f
blood) were treated with mefloquine (Roche Laboratories, Nutley,
NJ) and quinine (Marion Merrel Dow, Inc., Kansas City, KS).
Animals that developed anemia (TxA) were cured with drugs and
treated by iron supplementation and transfusion of whole blood
after the hematocrit fell below 20%. Animals that resolved
parasitemia without treatment are denoted noTx. Sera for the
ELISA and GIA analyses were collected on the day of challenge
(DOC).
ELISA Serology
ELISAs for detecting MSP142-specific Ab responses have been
described previously [47] as have the ELISAs for detecting
MSP142 domain-specific Ab responses (to p19, EGF1 and EGF2)
with E. coli expressed Ag [24].
Parasite Invasion/Growth Inhibition
3D7 and FVO P. falciparum parasites were maintained
asynchronously in media consisting of RPMI 1640 (Invitrogen)
with 25 mM HEPES, 7.5% w/v NaHCO3 and 10% A
+ pooled
human serum in A
+ E at 2–4% hct [48]. Parasites were
synchronized with a 40/70/90 percent Percoll gradient two days
prior to assay and the growth inhibitory activity of the sera
measured as described previously [49] after modification to reduce
sample volumes [50].
Statistical Methods
Fisher’s exact test was used to determine if treatment outcomes
(noTx, no treatment owing to self cure; TxA, treatment for
anemia; TxP, treatment for uncontrolled parasitemia) varied
according to vaccine regimen. A cumulative logit model was used
to evaluate the influence of adjuvant and antigen on the ordered
treatment outcome (ordering: noTx, TxA, TxP). The five models
that were compared are listed in Table 5. The best model was
picked by AIC [51]. An exact Wilcoxon-Mann-Whitney (WMW)
test was used when treatment outcomes were compared between
only two vaccine regimens.
Induction of strain specific Ab responses as measured by ELISA
was evaluated by using the Wilcoxon signed rank test. Cumulative
day 11 parasitemia (c-day 11 parasitemia) was calculated by
summing daily parasitemia from the day of challenge (DOC) until
the day the first animal in the study was treated for any reason (day
11). It was used as the continuous variable for evaluating the
correlation between serological responses and parasite responses.
General linear models (GLM) were used to evaluate the influence
of adjuvant and antigen on the induction of responses (c-day 11
parasitemia, growth inhibition, ELISA Ab level). For these
analyses c-day 11 parasitemia was transformed by log10. For the
GLM used to evaluate the relationship between the affect of
antigen and adjuvant on the ELISA Ab response level, log
transformations were not normally distributed. Instead, Box-Cox
analysis showed that the ideal transformation was ‘‘square root’’.
Growth inhibition responses were not transformed for testing in
the GLM. All correlations were evaluated with Pearson’s test after
testing responses for normality with the Kolgomorov-Smirnov test.
The calculations for the cumulative logit model were done using
the MASS package version 7.2–29 in R version 2.4.0. ROC
calculations were also prepared in R but using the ROCR package
[52]. All other calculations were done using MiniTab Statistical
Software, Release 14.1. All p-values are two-sided.
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